In this large hVISA clinical study, authors find that heteroresistance is not only common but links to clinical failure. The team proposes a new outcome-based test threshold (PAP–AUC 0.65) to guide safer therapy.
- Nikos Fatsis-Kavalopoulos
- Yong Kyun Kim
- Dan I. Andersson